Eileen M OReilly
Overview
Explore the profile of Eileen M OReilly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
328
Citations
12617
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al.
Nature
. 2025 Feb;
PMID: 39972124
A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA-lipoplex vaccines against somatic mutation-derived neoantigens may...
2.
Dekker E, van Klaveren D, Verkolf E, de Wilde R, Besselink M, OReilly E, et al.
Br J Surg
. 2025 Feb;
112(2).
PMID: 39967445
Background: Which patients with locally advanced pancreatic cancer may benefit from surgical exploration after induction treatment remains debated. The aim of this retrospective cohort study was to identify independent factors...
3.
Lucotti S, Ogitani Y, Kenific C, Geri J, Kim Y, Gu J, et al.
Cell
. 2025 Feb;
PMID: 39938515
Cancer is a systemic disease with complications beyond the primary tumor site. Among them, thrombosis is the second leading cause of death in patients with certain cancers (e.g., pancreatic ductal...
4.
Wainberg Z, Melisi D, Macarulla T, Pazo Cid R, Chandana S, De La Fouchardiere C, et al.
Future Oncol
. 2025 Feb;
21(7):765-774.
PMID: 39935331
No abstract available.
5.
Schram A, Goto K, Kim D, Macarulla T, Hollebecque A, OReilly E, et al.
N Engl J Med
. 2025 Feb;
392(6):566-576.
PMID: 39908431
Background: Neuregulin 1 () fusions are recurrent oncogenic drivers found in multiple solid tumors. NRG1 binds to human epidermal growth factor receptor 3 (HER3), leading to heterodimerization with HER2 and...
6.
Dekker E, Janssen Q, van Dam J, Strijk G, Verkolf E, Kandala S, et al.
Ann Surg Oncol
. 2025 Feb;
PMID: 39907876
Background: This study aimed to investigate the feasibility and yield of blood sample collection in an investigator-initiated nationwide randomized controlled trial (RCT). Methods: In the PREOPANC-2 trial, 375 patients with...
7.
Eikenboom E, Nasar N, Seier K, Gonen M, Spaander M, OReilly E, et al.
Ann Surg Oncol
. 2025 Jan;
PMID: 39873847
No abstract available.
8.
Sharib J, Rhodin K, Liu A, McIntyre S, Bartholomew A, Masoud S, et al.
Ann Surg Oncol
. 2025 Jan;
32(4):2501-2502.
PMID: 39873846
No abstract available.
9.
Sharib J, Rhodin K, Liu A, McIntyre S, Bartholomew A, Masoud S, et al.
Ann Surg Oncol
. 2025 Jan;
32(4):2456-2466.
PMID: 39827317
Background: Randomized data suggest improved survival with adjuvant chemotherapy for biliary tract cancers; however, subset analyses of intrahepatic cholangiocarcinoma (IHC) show limited survival benefit. This study evaluated the impact of...
10.
Varghese A, Perry M, Chou J, Nandakumar S, Muldoon D, Erakky A, et al.
Nat Med
. 2025 Jan;
31(2):466-477.
PMID: 39753968
Nearly all pancreatic adenocarcinomas (PDAC) are genomically characterized by KRAS exon 2 mutations. Most patients with PDAC present with advanced disease and are treated with cytotoxic therapy. Genomic biomarkers prognostic...